Select Page ::

Global Travel Bag Market Report Explores Share, Development By Companies Outlook, Growth Prospects And 2026 Key Opportunities Forecast – Cole of Duty

Posted on July 24, 2020 by Danzig

Travel Bag Market is systematic exploration that delivers key statistics on the market status of the development trends, competitive landscape analysis, and key regions development status. The report has included strong players and analyses their limitations and strong points of the well-known players through SWOT analysis. This Report covers growing trends that are linked with major opportunities for the expansion of the Travel Bag industry.

Get Free Sample Report(including full TOC, Tables and Figures): @ https://www.globalmarketers.biz/report/life-sciences/global-travel-bag-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/155811#request_sample

Ace Co. Ltd.EverestSamsonite Company StoresVIP Industries Ltd.CrownUnited States Luggage Company (LLC)TumiTravelpro International Inc.RimovaAmerican TouristerEagle CreekAntlerShanghai Fochier Intel Co. Ltd.Targus Group International Inc.Delsey SA

The Geographical Analysis Covers the Following Regions

The recent outbreak of the COVID-19 (Corona Virus Disease) Provide extra commentary on the newest scenario, an economic slowdown on the overall industry. In addition to this, the report also includes the development of the Travel Bag market in the major regions across the world.

Note: Upto 30% Discount: Get this reports in Discounted Price

Ask For Discount: https://www.globalmarketers.biz/discount_inquiry/discount/155811

Global Travel Bag Market Segmentation: By Types

MenWomenKids

Global Travel Bag Market Segmentation: By Applications

Travel PacksLightweight Carry-OnsWheeled Duffel Bags and Rolling LuggageBackpacks and Wheeled Backpacks

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.globalmarketers.biz/report/life-sciences/global-travel-bag-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/155811#inquiry_before_buying

This research report represents a 360-degree overview of the competitive landscape of the Travel Bag Market. Furthermore, it offers enormous statistics relating to current trends, technological advancements, tools, and methodologies.

Global Travel Bag Market Research Report 2020

Chapter 1 About the Travel Bag Industry

Chapter 2 World Market Competition Landscape

Chapter 3 World Travel Bag Market share

Chapter 4 Supply Chain Analysis

Chapter 5 Company Profiles

Chapter 6 Globalization & Trade

Chapter 7 Distributors and Customers

Chapter 8 Import, Export, Consumption and Consumption Value by Major Countries

Chapter 9 World Travel Bag Market Forecast through 2027

Chapter 10 Key success factors and Market Overview

It concludes by throwing light on the recent developments that took place in the Travel Bag market and their influence on the future growth of this market.

Table of Content & Report Detail @ https://www.globalmarketers.biz/report/life-sciences/global-travel-bag-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/155811#table_of_contents

Virtual tourism in Africa takes off amid the coronavirus pandemic – DW (English)

Posted on July 24, 2020 by Danzig

The sun rises slowly above the horizon of the African savanna. Against its glowing light can be seen the silhouettes of an elephant family rambling through the grassland on their quest for the nearest waterhole. Impalas and zebras make their way through the wilderness, the birds chirp and it can be sensed that the day is going to be a hot one.

This scene in the Sabi Sand Game Reserve in Mpumalanga, one of the best-known safari regions of South Africa, seems very real. But, in fact, the tourists who are enjoying it are not sitting in jeeps, but at home watching it on their smartphones and tablets. The safari itself is really taking place, however, and, as in real life, every trip is different, adding to the pleasure of such virtual experiences.

In the Kenyan game reserve Ol Pejeta you can go on a virtual safari with rangers.

Since the coronavirus pandemic broke out, the tourism industry has collapsed across all the countries in Africa. National parks and hotels are empty and there is no trace of tourists, as they are all stuck at home.

But several African tourism associations have come up with the idea of supplying avid travelers with digital impressions of the continent during the pandemic. Virtual tourism is on the rise.

Safaris at home

Safaris in Kenya, strolls through the Namib desert in Namibia, paragliding in South Africa or standing on the edge of the Victoria Falls at the border between Zambia and Zimbabwe: All of these experiences can now be enjoyed at home by virtual tourists like Juan Santiago.

Santiago, who hails from the Spanish capital, Madrid, has already visited Kenya a couple of times at this time of year to watch the migration of wildebeest in the Maasai Mara game reserve, a phenomenon that has often been called one of the Wonders of the World.

But this year, things are different. Instead of going to Kenya, Santiago is paying a virtual visit to the Nairobi National Park. "If the safari is led well, you have the atmosphere of the Nairobi National Park at home. Everything happens in real time," he says. "Even if my family tours Kenya without me after the coronavirus pandemic, this technology lets me accompany them virtually."

Conventional safaris are important for earning foreign currencies, especially in eastern and southern Africa.

Read more:Protecting South African wildlife from poaching during the coronavirus pandemic

A chance to survive

Kenya has already lost more than $750 million (656 million) in revenue from tourism since the first case of COVID-19 in the country. That is why, in June, the tourism authority there initiated a live-stream drive as part of its #TheMagicAwaits campaign. It is meant to give the world a taste of what awaits in Kenya when the country is open to visitors once more, says Betty Radier, the managing director of the Kenya Tourism Board.

"People are online and looking for places they could travel to. That is a great opportunity for us to present ourselves live as a destination," she told DW. Sixteen different destinations in Kenya are being live-streamed.

A taste of things to come

This concept is also working in South Africa. The tourism authority in Cape Town, for example, has launched the campaign We Are Worth Waiting For. It is offering ways to enjoy the city virtually, including tours on Robben Island, with its former prison, and Table Mountain.

The managing director of Cape Town Tourism, Enver Duminy, describes it as a long-distance love affair.

"What we have done using technology during COVID-19 is to use social media and campaigns to remind tourists of why they fell in love with the destination in the first place," Duminy told DW. "We give images of what you are longing for, of what you experienced the last time you were here. And hopefully we can connect and continue that love affair when you visit us. Technology is more of an enabler that allows us to transit in space and time."

"Virtual tourism is a great opportunity for seeing whether you want to visit a particular destination for real," says Gerald Ferreira, the founder of the Virtual Reality Company in South Africa. "People can also try out what adventure tourism is like before they try something like bungee jumping, for example."

Read more:Faraway peaks and unreachable cities virtual travel is all that's possible for the time being

Rapid growth

According to figures from the UN's World Tourism Organization (UNWTO), 74% of African governments were not allowing tourists into their countries at the start of June. Before the pandemic broke out, Africa was the fastest-growing tourism region. In 2018, some 67 million tourists visited the continent, bringing $38 billion in revenue. In 2019, the number of tourists increased by 4.2%, according to preliminary figures. And Africa could have reckoned with an increase of 3-4% in 2020.

But then, COVID-19 arrived on the scene. The World Travel and Tourism Council (WTTC) puts the number of jobs lost in Africa's tourism sector alone at almost 8 million. This has made seeking alternatives imperative.

But can virtual tourism replace real travel? Or could it even cause long-term damage to the tourism industry, with potential travelers staying away, content with visiting Africa virtually?

Read more:How COVID-19 is destroying Africa's tourism industry

Itchy feet syndrome

Patrick Karangwa, a computer scientist from Rwanda, does not think it will. He offers virtual tours through the capital, Kigali.

"I don't see myself as competing with traditional tourism, but as a partner," he told DW. "I create an additional layer of information that encourages people to travel to places. It is really an advantage for travel businesses, hotels, restaurants and the industry in general."

Enver Duminy in Cape Town is also banking on people's continued wanderlust. "Virtual reality allows more immersive experiences, even though at this stage it does not allow you to touch and taste and smell. It only allows you to see. I think it is in our DNA; we need to connect, to see, to touch, to hug."

In a few weeks' time, the first package tourists from Europe are due in Rwanda again. Tanzania, known for its lax approach to the coronavirus crisis, is already welcoming tourists, and Namibia has reopened its national parks. Kenya will allow tourists in from August 1 and South Africa's tourism industry hopes to be able to open for business from September 2020 whether that will really be the case, however, remains uncertain, as cases of coronavirus infection are currently rising. Countries like Uganda will probably have to wait a bit longer.

Read more:Corona-hit tourism in Kenya leaves elephant conservation 'staring at an uncertain future'

Animal welfare benefits

Juan Santiago in Madrid is not worried by this. Since the pandemic started, he has already taken a virtual look at the famous archaeological finds and collections in the Nairobi National Museum.

Even if he likes to travel in these countries in person, he believes in the future of virtual tourism. "One day, we will all be able to see the giraffes in Nairobi from all over the world; you'll go to work at 8 o'clock and watch the giraffes on live screens in the office," he says. "That will be good for nature conservation because nature fans like me would then donate for these giraffes, rhinoceroses or elephants."

Anyone who already has itchy feet can only hope that trips to Africa will soon be possible again. But for those who are content with virtual travel as well the world is already open.

See the original post:

Virtual tourism in Africa takes off amid the coronavirus pandemic - DW (English)

A functional genomics approach to investigate the differentiation of iPSCs into lung epithelium at air-liquid interface. – Physician’s Weekly

Posted on July 24, 2020 by Danzig

The availability of robust protocols to differentiate induced pluripotent stem cells (iPSCs) into many human cell lineages has transformed research into the origins of human disease. The efficacy of differentiating iPSCs into specific cellular models is influenced by many factors including both intrinsic and extrinsic features. Among the most challenging models is the generation of human bronchial epithelium at air-liquid interface (HBE-ALI), which is the gold standard for many studies of respiratory diseases including cystic fibrosis. Here, we perform open chromatin mapping by ATAC-seq and transcriptomics by RNA-seq in parallel, to define the functional genomics of key stages of the iPSC to HBE-ALI differentiation. Within open chromatin peaks, the overrepresented motifs include the architectural protein CTCF at all stages, while motifs for the FOXA pioneer and GATA factor families are seen more often at early stages, and those regulating key airway epithelial functions, such as EHF, are limited to later stages. The RNA-seq data illustrate dynamic pathways during the iPSC to HBE-ALI differentiation, and also the marked functional divergence of different iPSC lines at the ALI stages of differentiation. Moreover, a comparison of iPSC-derived and lung donor-derived HBE-ALI cultures reveals substantial differences between these models. 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

PubMed

Read the original post:

A functional genomics approach to investigate the differentiation of iPSCs into lung epithelium at air-liquid interface. - Physician's Weekly

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic…

Posted on July 24, 2020 by Danzig

NEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, and the University of Connecticut School of Medicine (UConn), today announced a research collaboration and license agreement to accelerate the development of a next-generation short hairpin RNA (shRNA)-based therapeutic for Angelman syndrome and potentially other indications. The most common cause of Angelman syndrome is the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), which plays a critical role in nerve cell communication, resulting in impaired tonic inhibition. An shRNA-based therapeutic may address this underlying genetic cause of Angelman syndrome by reducing the expression of UBE3A-antisense, potentially restoring the function of UBE3A. This genetic approach may be used in combination with OV101 (gaboxadol), Ovids novel, small-molecule delta ()-selective GABAA receptor agonist, to restore tonic inhibition and address the underlying symptomology of individuals with Angelman syndrome. OV101 is currently being evaluated in the pivotal Phase 3 NEPTUNE trial in Angelman syndrome, with topline results expected in the fourth quarter of 2020.

Under the terms of the research collaboration, Ovid will work closely with UConns Stormy J. Chamberlain, Ph.D., and gain exclusive access to identified genetic sequences for a potential shRNA-based therapeutic. Ovid plans to validate select sequences and leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance an shRNA-based therapeutic into clinical studies. Dr. Chamberlain is a recognized leader in the field of Angelman syndrome and UBE3A research and currently serves as the John and Donna Krenicki Associate Professor of Genomics and Personalized Healthcare in UConns Genetics and Genome Sciences Department. In addition, Dr. Chamberlain chairs the Angelman Syndrome Foundation (ASF) Scientific Advisory Committee and is a member of the Dup15q Alliance Scientific Advisory Board. Ovid will also work closely with UConns Noelle Germain, Ph.D., Assistant Professor of Genetics and Genome Sciences on these efforts.

Ovid is deeply committed to the Angelman syndrome community. We have made great progress and are excited to see the topline data from our Phase 3 NEPTUNE trial with OV101 expected in Q4 2020, said Amit Rakhit, M.D., MBA, President and Chief Medical Officer of Ovid Therapeutics. We believe OV101 has the potential to serve as a core therapy for this disorder and are now focused on building a comprehensive and strategic Angelman syndrome longer term pipeline. If successful, OV101 may be used in combination with genetic approaches in the future to address the needs of Angelman syndrome. This collaboration with Drs. Chamberlain and Germain, both accomplished scientific leaders in the field of Angelman syndrome, will enable us to accelerate and share in their mission to identify and develop next-generation genetic therapies. Together with our early-stage microRNA approach, this research collaboration now provides us with additional targets against this disorder, greater strategic optionality, and underpins our broad capability to bring new therapies to individuals living with Angelman syndrome both near-term and into the future.

Our lab shares in Ovids demonstrated commitment to advance innovative therapeutic options for Angelman syndrome, stated Dr. Chamberlain. An shRNA therapeutic can target the genetic cause of Angelman syndrome at its source and may offer potential advantages to other next-generation approaches, including antisense oligonucleotide therapy, via a lower rate of degradation and turnover and plasmid delivery allowing for a less-frequent dosing profile. Ovid is uniquely positioned to accelerate an shRNA therapeutic through late preclinical and clinical development, and our lab looks forward to working with the team at Ovid towards our common objective of impacting the lives of individuals living with Angelman syndrome and their families.

About Angelman Syndrome Angelman syndrome is a rare genetic condition that is characterized by a variety of signs and symptoms. Characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety. The most common cause of Angelman syndrome is the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), which plays a critical role in nerve cell communication, resulting in impaired tonic inhibition. Individuals with Angelman syndrome typically have normal lifespans but are unable to live independently. Therefore, they require constant support from a network of specialists and caregivers. Angelman syndrome affects approximately 1 in 12,000 to 1 in 20,000 people globally.

There are no approved therapies by the U.S. Food and Drug Administration (FDA), European Medicines Agency or rest-of-world for Angelman syndrome, and treatment primarily consists of behavioral interventions and pharmacologic management of symptoms.

Angelman syndrome is associated with a reduction in tonic inhibition, a function of the delta ()-selective GABAA receptor that allows a human brain to decipher excitatory and inhibitory neurological signals correctly without being overloaded. If tonic inhibition is reduced, the brain becomes inundated with signals and loses the ability to separate background noise from critical information.

Ovid is developing OV101 for the treatment of Angelman syndrome to potentially restore tonic inhibition and thereby address several core symptoms of Angelman syndrome. Ovid is conducting a pivotal Phase 3 clinical trial with OV101 in Angelman syndrome (NEPTUNE), with topline results expected in the fourth quarter of 2020. In addition, Ovid is also exploring OV881, a microRNA approach that may reduce the expression of UBE3A-antisense and potentially restore UBE3A expression.

About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Companys most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit http://www.ovidrx.com.

About UConnUConn Health is Connecticuts only public academic medical center. Based on a 206-acre campus in Farmington, UConn Health has a three-part mission: research, teaching and patient care. Home to the UConn School of Medicine, School of Dental Medicine and UConn John Dempsey Hospital with over 5,000 employees supporting nearly 1,000 students, over 800,000 annual patient visits, and innovative scientific research contributing to the advancement of medicine. For more information, visit health.uconn.edu.

Ovid Forward-Looking StatementsThis press release includes certain disclosures that contain forward-looking statements, including, without limitation, statements regarding: development of short hairpin RNA based therapeutics, development of combination therapies, potential benefits of OV101, anticipated reporting schedule of clinical data for OV101 and the potential benefits and value of this collaboration. You can identify forward-looking statements because they contain words such as will, appears, believes and expects. Forward-looking statements are based on Ovids current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovids filings with the Securities and Exchange Commission under the caption Risk Factors. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovids business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Ovid Therapeutics Contacts

Investors and Media:Ovid Therapeutics Inc.Investor Relations & Public Relationsirpr@ovidrx.com

Investors: Steve KlassBurns McClellan, Inc.sklass@burnsmc.com(212) 213-0006

Media:Katie Engleman1ABkatie@1abmedia.com

UConn ContactJessica McBride, PhDjessica.mcbride@uconn.edu860-878-5058

Read this article:

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic...

Global Bioinformatics Market To See Booming Worldwide | Top Key Players- Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc. – 3rd Watch News

Posted on July 24, 2020 by Danzig

A recent report published by QMI on bioinformatics market is a detailed assessment of the most important market dynamics. After carrying out thorough research on the market of bioinformatics historical as well as current growth parameters, business expectations for growth are obtained with utmost precision. The study identifies specific and important factors affecting the market for bioinformatics during the forecast period. It can enable manufacturers of bioinformatics to change their production and marketing strategies in order to envisage maximum growth. The market report on bioinformatics offers detailed information for stakeholders in the most comprehensive way on the current and future growth prospects of the demand for bioinformatics market.

To Request Sample Premium Reports:https://www.quincemarketinsights.com/request-sample-60484?utm_source=SSK&utm_medium=3WN&utm_campaign=SSK

This report provides comprehensive taxonomy and the description of industry-related products, applications and end-user channels for the bioinformatics market. This report also provides insight into market concepts for phase. This contains opportunity analysis which provides information on the most relevant macroeconomic and microeconomic factors affecting market revenues and estimates for the phase. The market background is discussed in the report which sheds a light on the key drivers, threats, patterns and opportunities in the demand for bioinformatics market. A global overview has been presented for bioinformatics products, supply chain analysis and hazard analysis, which is expected to help readers identify the key factors that support the growth of the demand for bioinformatics market. The report discusses the regulatory scenario affecting approvals for the products, across leading regions. It also provides information on the demand of the bioinformatics market adopted in leading countries. It includes a specific list of retailers and manufacturers dealing in bioinformatics market. Readers will also be able to find regional developments and regulations that impact market growth. Significant growth prospects are given for countries which also include key regional developments and factors that influence the growth of the demand for bioinformatics market. The report studies business patterns of top companys like- fujifilm holdings corporation, analogic corporation, siemens healthcare, esaote s.p.a, toshiba medical systems corporation, ge healthcare, philips healthcare, hitachi medical corporation, and mindray medical international ltd

Get TOC For The Overview Of The Premium Report:https://www.quincemarketinsights.com/request-toc-60484?utm_source=SSK&utm_medium=3WN&utm_campaign=SSK

Bioinformatics market growth is expected to gain high momentum during the forecast period due to increasing demand for imaging devices for diagnostics applications. An ceiling-mounted surgical lights is a medical imaging device, which uses high-frequency waves to visualize the internal organs of the body such as blood vessels, kidney, liver, human foetus, heart, etc. This market is gaining momentum, owing to the increase in the number of hospitals and adoption of technologically advanced devices, which can serve the purpose for both diagnostics and therapeutics. Moreover, the cumulative prevalence of cancer is driving the demand for early detections and minimization of expenses. According to the Cancer Research Institute (CRI), there were approximately 17 million new cases of cancer globally, as of 2017, which is also fuelling the demand for ultrasound devices.

Segment Analysis

The bed head multifunctional belt market has been segmented by type (platforms, tools, services), by applications (preventive medicine, molecular medicine, gene therapy drug development). Based on portability, the market can be divided into trolley/cart and compact/handheld. Based on application, the market has been divided into radiology, gynaecology, urology, cardiology, orthopaedic/musculoskeletal, and others. Owing to the growing incidences of stem cell-based injuries and the demand for high-quality diagnostic procedures, the radiology segment is expected to lead. The market has been studied for North America, Western Europe, Eastern Europe, Asia Pacific, and Rest of the World.

Key Factors Impacting Market Growth:

Regional Outlook:

North America, Western Europe, and Asia Pacific by region are estimated to dominate the ultrasound market during the forecast period. These regions have been market leaders for the overall healthcare sector in terms of technological developments and advanced medical treatments. Moreover, the government policies have been favourable for the growth of the healthcare infrastructure in these regions. North America and Western Europe have an established healthcare infrastructure for product innovations and early adaptations. This is expected to drive the demand for ultrasound market during the forecast period.

The US, Germany, France, UK, Canada, and Spain have been some the major markets in the region. Asia Pacific is estimated to register one of highest CAGR for ultrasound market during the forecast period. This region has witnessed strategic investments by global companies to cater the growing demand in the recent years. China, Japan, India, South Korea, and Australia are amongst some of the key countries for ultrasound market in the region. Other regions including Middle East, Eastern Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets for ultrasound during the forecast period.

Speak To Analyst before Buying This: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-60484?utm_source=SSK&utm_medium=3WN&utm_campaign=SSK

Market Segmentation:

By Type Platforms Tools Services

By Applications Preventive Medicine Molecular Medicine Gene Therapy Drug Development

By Region:

Major Companies:Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc., CLC bio A/S, Agilent Technologies Inc., GenoLogics Life Sciences Software, Inc., Life Technologies Corporation, Illumina, Inc.

Reasons to Buy This Report:

Customization:

We provide customization of the study to meet specific requirements:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: US +1 208 405 2835 / UK +44 121 364 6144 / APAC +91 706 672 4848

Email:[emailprotected]

Web: http://www.quincemarketinsights.com

Cytokine-induced molecular responses in airway smooth muscle cells inform genome-wide association studies of asthma. – Physician’s Weekly

Posted on July 24, 2020 by Danzig

A challenge in the post-GWAS era is to assign function to disease-associated variants. However, available resources do not include all tissues or environmental exposures that are relevant to all diseases. For example, exaggerated bronchoconstriction of airway smooth muscle cells (ASMCs) defines airway hyperresponsiveness (AHR), a cardinal feature of asthma. However, the contribution of ASMC to genetic and genomic studies has largely been overlooked. Our study aimed to address the gap in data availability from a critical tissue in genomic studies of asthma.We developed a cell model of AHR to discover variants associated with transcriptional, epigenetic, and cellular responses to two AHR promoting cytokines, IL-13 and IL-17A, and performed a GWAS of bronchial responsiveness (BRI) in humans.Our study revealed significant response differences between ASMCs from asthma cases and controls, including genes implicated in asthma susceptibility. We defined molecular quantitative trait loci (QTLs) for expression (eQTLs) and methylation (meQTLs), and cellular QTLs for contractility (coQTLs) and performed a GWAS of BRI in human subjects. Variants in asthma GWAS were significantly enriched for ASM QTLs and BRI-associated SNPs, and near genes enriched for ASM function, many with small P values that did not reach stringent thresholds of significance in GWAS.Our study identified significant differences between ASMCs from asthma cases and controls, potentially reflecting trained tolerance in these cells, as well as a set of variants, overlooked in previous GWAS, which reflect the AHR component of asthma.

PubMed

See more here:

Cytokine-induced molecular responses in airway smooth muscle cells inform genome-wide association studies of asthma. - Physician's Weekly

Coronavirus morning update: Public schools to shut, and Covid corruption warning – Health24

Posted on July 24, 2020 by Danzig

WHAT'S HAPPENING IN SA

Cases update:

The latest number of confirmed cases is 408 052.

According to the latest update, 6 093 of deaths have been recorded in the country.

There have been 236 260 recoveries.

So far, just over 2.6 million tests have been conducted, with 46 632 new tests.

READ MORE | All the confirmed cases of coronavirus in SA

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. – GlobeNewswire

Posted on July 24, 2020 by Danzig

Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriads Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors

SALT LAKE CITY, July 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel M. Skovronsky, M.D., Ph.D., age 47, to its Board of Directors, effective immediately, expanding the Board to ten members. Additionally, Dr. Skovronsky was appointed to the Research and Product Innovation Committee of Myriads Board.

Dr. Skovronsky serves as Chief Science Officer and President of Lilly Research Laboratories at Eli Lilly and Company. He previously served as the Founder and Chief Executive Officer of Avid Radiopharmaceuticals, Inc. which used non-invasive imaging to detect the early changes in the brain related to Alzheimers disease. Dr. Skovronsky received his M.D., Ph.D. from University of Pennsylvania where he also completed sub-specialty training in neuropathology.

We are honored to welcome Dr. Skovronsky to the Myriad Board, said Louise Phanstiel, Chair of the Board of Myriad. Dan brings a wealth of experience and expertise in research and development in multiple areas related to our diagnostic product development, including oncology, neuroscience, and anti-inflammatory diseases. He will be instrumental in providing product development strategic insights in executing our global strategy for molecular diagnostics and precision medicine.

The Company also announced today that Director, Vice Chair of the Board, Walter (Wally) Gilbert, Ph.D., will retire from the board at the Companys Annual Meeting of Stockholders in December 2020. Dr. Gilbert, co-founder of Myriad, has been on the board since March 1992. Dr. Gilbert received a Nobel Prize in Chemistry in 1980 for his development of a rapid DNA sequencing technology. I am proud that Myriad has grown to realize its founders dream of using tests based on genetic information to identify a patients predisposition to disease, said Dr. Gilbert. Myriad is dedicated to providing critical, life-changing information to people to help define their individual medical needs. I have enjoyed helping the company grow over the years. I am confident that Myriads important work for patients will continue.

In commenting on Dr. Gilberts pending retirement, Louise Phanstiel said, The Board owes a tremendous debt of gratitude to Wally for all of his countless contributions to the company and to the board over the years. His relentless focus on the pursuit of scientific excellence and compassion for our patients as well as our Myriad team are qualities we all aspire to emulate. The board, the company and I will greatly miss his wisdom, counsel and passion. We wish Wally all the best.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Dr. Skovronsky providing product development strategic insights in executing the Companys global strategy for molecular diagnostics and precision medicine; Dr. Gilbert retiring from the Companys board at the Companys Annual Meeting of Stockholders in December 2020; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Jared Maxwell (801) 505-5027 jmaxwell@myriad.com

Investor Contact: Scott Gleason(801) 584-1143sgleason@myriad.com

See more here:

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. - GlobeNewswire

Encoded Therapeutics Raises $135M in Series D Financing – FinSMEs

Posted on July 24, 2020 by Danzig

Encoded Therapeutics, Inc., a South Francisco, Calif.-based precision gene therapy company, raised $135m in Series D financing.

The round was led by GV (formerly Google Ventures) with participation from Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, SoftBank Vision Fund 21, and additional unnamed investors. In conjunction with the funding, David Schenkein, M.D., general partner and co-leader of GVs life sciences team, will join the Encoded Board of Directors as an observer.

Led by co-founder and chief executive officer, Kartik Ramamoorthi, Ph.D., Encoded is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. It is advancing its lead asset, ETX101, for the treatment of SCN1A+ Dravet Syndrome by leveraging a discovery engine that combines biological and computational approaches to identify and screen human DNA sequences known as regulatory elements at a high throughput scale.

The company intends to use the funds to advance its lead asset, ETX101, which was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA) for the treatment of SCN1A+ Dravet Syndrome.

Proceeds from the Series D will be used to conduct clinical trial activities including a natural history study to better understand the progression of SCN1A+ Dravet Syndrome as well as first-in-human trials for ETX101. Additionally, the funds will support progression of the companys pipeline of gene therapies being evaluated for additional pediatric CNS disorders.

FinSMEs

23/07/2020

Original post:

Encoded Therapeutics Raises $135M in Series D Financing - FinSMEs

MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy – Xconomy

Posted on July 24, 2020 by Danzig

XconomyNew York

A gene therapy being jointly developed by MeiraGTx and Johnson & Johnson to treat an inherited disease of the retina that leads to blindness improved patients vision after six months, data that the companies say is enough to move the potentially long-lasting treatment into pivotal testing.

The condition, called X-linked retinitis pigmentosa, is part of a group of vision disorders that collectively represent the most common cause of inherited blindness. X-linked RP, or XLRP, the most aggressive form of retinitis pigmentosa, significantly impairs patients quality of life as the disease progresses. No treatments currently exist.

The MeiraGTx (NASDAQ: MGTX) treatment is designed for patients whose XLRP is caused by mutations in the gene RPGR, which cause about 70 percent of XLRP cases and up to 20 percent of all retinitis pigmentosa cases. MeiraGTxs gene therapy is delivered via subretinal injection.

A Phase 1/2 trial, underway at five sites in the US and UK, tested three doses in 10 male patients age 5 and older for safety and tolerability. In each patient one eyethe one with worse sightwas treated; the other eye was used as a control.

Secondary goals included retinal sensitivity, which after six months had improved or stabilized in five of the seven in the low and intermediate dose groups, according to the interim data. No improvement was observed in the high dose cohort; it wont be tested in future trials. Signs of improvement were detected at the first assessment, which took place at three months, improvements that were generally sustained or increased at the next evaluation.

Most of the adverse events recorded were associated with the surgical procedure used to deliver the treatment, according to MeiraGTx; two of three patients in the high-dose cohort experienced inflammation, which was controlled with steroids.

The data were presented at the annual meeting of the American Society of Retina Specialists, which was held virtually. The interim results support advancing the treatment into a Phase 3 triala first for MeriaGTx, which was founded about five years ago, president and CEO Zandy Forbes said on a conference call Friday.

Johnson & Johnson (NYSE: [[ticker:J&J]]) made a bet on the gene therapy pipeline being developed by MeiraGTx in January 2019, when the companies inked a $100 million deal giving the pharma giant rights to the biotechs investigational XLRP treatment, plus others in its pipeline, as part of a pact to jointly develop and commercialize gene therapies to treat inherited retinal diseases. Under the terms of that deal, MeiraGTx is eligible for up to $340 million more based on the programs progression.

Including the XLRP program, MeiraGTxwhich has offices in London and New Yorkis advancing six clinical-stage programs, half of them under its collaboration with J&J. The companys initial focus is on diseases that impact the eye, central nervous system, and salivary glands.

The first-ever gene therapy approved in the US, Spark Therapeutics voretigene neparvovec (Luxturna), was for patients with an inherited retinal disease that can lead to blindness. Its 2018 approval led to the companys acquisition the following year by Roche, which splashed out $4.8 billion for the Philadelphia-based firm. Spark priced its treatment at $850,000.

Image: iStock/monkeybusinessimages

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

More here:

MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy - Xconomy

Investment Analysis On: Gene Therapy MARKET ? GROWING TRADE AMONG EMERGING ECONOMIES OPENING NEW OPPORTUNITIES (2020-2026) – 3rd Watch News

Posted on July 24, 2020 by Danzig

Global Gene Therapy Market Research Report 2020: COVID-19 Outbreak Impact Analysis

The Gene Therapy market research report drafted by Brand Essence Market Research elucidates relevant market and competitive insights as well as regional and consumer information. In a nutshell, the research study covers every pivotal aspect of this business sphere that influences the existing trends, profitability position, market share, market size, regional valuation, and business expansion plans of key players in the Gene Therapy market.

Download Premium Sample of the Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=165836&RequestType=Sample

Latest research report on Gene Therapy Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the markets growth.

The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

This report focuses on the global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.

The key players covered in this study RetroSense Therapeutics REGENXBIO AGTC

Market segment by Type, the product can be split into Subretinal Intravitreal Unspecified

Market segment by Application, split into Monotherapy Combination Therapy

In this study, the years considered to estimate the market size of Gene Therapy for Age-related Macular Degeneration are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

Market segment by Regions/Countries, this report covers United States Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. To present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by product type, market and key regions.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

>>>>Get Full Customize report@ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=165836&RequestType=Customization

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

The Essential Content Covered in the GlobalGene Therapy Market Report:

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report provides a 6-year forecast (2020-2026) assessed based on how the Gene Therapy market is predicted to grow in major regions like USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Strategic Points Covered in TOC:

Chapter 1:Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Gene Therapy market.

Chapter 2:Evaluating the leading manufacturers of the global Gene Therapy market which consists of its revenue, sales, and price of the products.

Chapter 3: the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4:Presenting global Gene Therapy market by regions, market share and revenue and sales for the projected period.

Chapters 5, 6, 7, 8 and 9:To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Top Trending Reports:

https://www.marketwatch.com/press-release/silver-dressings-bandages-market-size-industry-analysis-report-regional-outlook-application-development-potential-price-trends-competitive-market-share-forecast-20202025-2020-07-22?tesla=y

https://sites.google.com/view/themarkets/biotechnology/bioinformatics-service-market-expected-to-reach-4-96-billion-by-2026

https://sites.google.com/view/themarkets/heavy-industry/garden-furniture-market-expected-to-reach-usd-20032-93-million-by-2025

https://www.marketwatch.com/press-release/uk-anhydrous-milk-fat-market-size-share-growth-opportunities-and-market-forecast-2020-to-2025-2020-07-22?tesla=y

https://teletype.in/@nikhils/MjSVWuqus

Read the rest here:

Investment Analysis On: Gene Therapy MARKET ? GROWING TRADE AMONG EMERGING ECONOMIES OPENING NEW OPPORTUNITIES (2020-2026) - 3rd Watch News

National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed…

Posted on July 24, 2020 by Danzig

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that Dr. George K. Gittes, MD of the University of Pittsburgh, the lead researcher that developed the Companys potentially curative diabetes gene therapy, was awarded a grant of $2.59 million from the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases. The grant will assist Dr. Gittess development for his research project titled, Alpha Cell Conversion to Beta Cells in Non-human Primates and will build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes. In this project, Dr. Gittes research team will conduct important proof-of-principle studies in non-human primates as the last steps in preparation for human gene therapy clinical trials. This technology is the subject of an exclusive license agreement entered into between Genprex and the University of Pittsburgh in February of 2020.

We are excited to receive this funding to support our research in diabetic primates as we move toward human clinical trials, said Dr. George Gittes, Co-Scientific Director and Professor of Surgery at the UPMC (University of Pittsburgh Medical Center) Childrens Hospital of Pittsburgh and the lead researcher behind the diabetes gene therapy. We saw encouraging data in our preclinical mice studies, where the gene therapy reprogrammed pancreatic cells to restore normal blood glucose levels in diabetic mice for approximately four months, which could translate to decades in humans. More recently, preliminary results in non-human primates (monkeys) has also been very promising.

Dr. Gittes gene therapy for diabetes, which Genprex refers to as GPX-002, uses a novel infusion process comprised of an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the bodys immune system.

Diabetes affects approximately 10 percent of the U.S. population, or more than 34 million people. The diabetes gene therapy could not only become a new treatment option for millions of diabetes patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.

Dr. Gittes is the inventor of the gene therapy for diabetes, and he is eligible to receive royalties on this technology in the future.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

The project described in this press release is being supported by the National Institute of Diabetes and Digestive And Kidney Diseases of the National Institutes of Health under Award Number R01DK120377. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Link:

National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed...

GenScript launches CDMO segment "GenScript ProBio" at inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum…

Posted on July 24, 2020 by Danzig

At the Forum, GenScriptannounced the integration and upgrading of the original CDMO platform and the release of its latest brand GenScript ProBio. The new brand is dedicated to proactively providing end-to-end service from discovery to commercialization withprofessional solutions and efficientprocesses to accelerate drug development for customers.

For the past 16 years, since 2004, GenScript has gradually expanded its reach in the antibody drug discovery segment and established its capabilities in process development, helping many customers with their IND approvals during the period. In 2019, GenScript opened the Biologics Development Business Unit (BDBU), the predecessor of GenScript ProBio, and invited Dr. Brian Min, SeniorVicePresidentatSamsungBioepis, to join as CEO and form a management team with exceptional international perspectives. The core members of the team each have more than 15 years working experience at recognized international firms across the sector, including Roche, Pfizer, Henlius and Innovent, among others.

GenScript ProBio has established long-term partnerships with many industry leaders worldwide with the specific aim of advancing the development of the biopharmaceutical industry.

"The GenScript CDMO platform has established strong antibody capabilities within just 18 months since launch and has accumulated considerable experience in cell and gene therapy," said Dr. Brian Min at the launch of the brand."GenScript ProBio's one-stopantibody drug development solutions will proactively provide clients with end to end service from target to commercialization. Looking beyond China and the Asia Pacific region, many large multinational companies in the United States and Europe have also established productive partnerships with us. Operating under the principle of'Innovation through Collaboration', we fully expect to drive the development and progress of the whole industry together with our customers."

GenScript ProBio has been committed to accelerating the development of the cell therapy sector and helping firms within the sector accelerate the commercialization of cell therapy products. With the advent of the era of cell and gene therapy, GenScript ProBio plans to continue providing process optimization and production in line with international quality standards through a sound global supply chain network, empowering more partners worldwide to benefit patients anywhere at an early date.

GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO arm of the world's leading biotech company GenScript, providing end-to-end services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes to accelerate drug development for customers.

In line with the mission of "Innovation through Collaboration", GenScript ProBio is committed to helping customers shorten the time-to-market for biological drugs from discovery to commercialization, significantly lowering R&D costs and building a healthier future.

https://www.genscriptprobio.com/

SOURCE GenScript ProBio

https://www.genscriptprobio.com/

Link:

GenScript launches CDMO segment "GenScript ProBio" at inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum...

Gracell Expands Executive Team by Appointment of CMO Dr. Martina Sersch and CFO Dr. Kevin Xie – PRNewswire

Posted on July 24, 2020 by Danzig

SHANGHAI and SUZHOU, China, July 23, 2020 /PRNewswire/ --Internationally renowned clinical-stage immune cell and gene therapy company, Gracell Biotechnologies Co., Ltd. ("Gracell" or "the Company") has announced two appointments to the executive suite. Chief Medical Officer Dr. Martina Sersch, MD and Chief Financial Officer Kevin Xie, PhD, MBA both bringing extensive knowledge and leadership experience to Gracell. Along with CEO Dr. William Cao, Dr. Sersch and Dr. Xie joined Gracell in their respective functions to support the company's mission of providing novel cellular therapies for unmet medical needs.

"We are delighted that Dr. Martina Sersch and Dr. Kevin Xie joined Gracell," said Dr. William Cao, CEO of Gracell. "Gracell has achieved many significant milestones since its founding, and with the recent addition of Dr. Sersch and Dr. Xie to our executive leadership team, Gracell will be advancing faster to achieve future breakthroughs."

CMO Dr. Martina Sersch brings over 25 years of experience in academia and industry, as well as an exceptional wealth of talent and knowledge to the Company. Prior to Gracell, Martina was CMO of a Nasdaq-listed CAR-T and gene therapy company, leading the development of novel cell and gene therapies for rare diseases and oncology indications. In addition, she previously served roles of increasing responsibility in Oncology Development as well as Medical Affairs at Pfizer, Genentech/Roche and Amgen, including leading the development of CAR-T therapies, gene therapies and immuno-oncology products in hematology and solids tumors. She oversaw the development and successful filing activities of multiple early- and late-stage products regionally and globally including US, Europe and Asia. Dr. Sersch received her MD and doctorate degree from the University of Heidelberg in Germany.

"Gracell has made significant achievements in multiple projects developing FasTCAR and TruUCARTM platform which were recently presented at major conferences in the treatment for hematological malignancies and solid tumors," said Dr. Martina Sersch, "As CMO, I am excited to continue to lead an incredible team with very talented researchers in our quest in developing innovative medicines for people with high unmet medical need.

CFO Dr. Kevin Xie came to Gracell with extensive healthcare finance and investment experience in leadership positions. Prior to Gracell, Dr. Xie was most recently the President of Fosun Healthcare Holdings and Chief Representative of Fosun in New York. Before Fosun, Dr. Xie served in senior positions at multiple global healthcare investment funds for over ten years, including as the co-founder of Locust Walk Capital, healthcare sector head at Scopia Capital and a managing director at Great Point Partners. Dr. Xie holds an MBA from The Wharton School and a PhD in Chemistry from the City University of New York.

"After twenty years of investing and advising healthcare companies, I am excited to join Gracell to lead the Company's finance and business development activities, and together with R&D team to build Gracell to be a leader in cell and gene therapy industry," said Dr. Kevin Xie, "I can see Gracell is poised to translate its industry-leading research programs into the transformative treatments, which could change millions of patients' lives worldwide. By joining and leading Gracell's finance organization at this exciting stage of its development, I wish to help deliver that promise as the company progresses to the next phase of strategy."

About Gracell

Gracell Biotechnologies Co., Ltd. ("Gracell") is a clinical-stage biotechnology company, committed to developing highly efficacious and affordable cell and gene therapies for the treatment of cancer. Gracell is dedicated to resolving the remaining challenges in CAR-T, such as high production costs, lengthy manufacturing process, lack of off-the-shelf products, and inefficacy against solid tumors. Led by a group of world-class scientists, Gracell is advancing FasTCAR (overnight production and younger cell phenotype), TruUCAR (off-the-shelf), DualCAR and EnhancedCAR T cell therapies for leukemia, lymphoma, myeloma, and solid tumors.

CONTACT:

Kevin XIECFO[emailprotected]

Linc HEBusiness Development and Public Relations[emailprotected] +86-21-6403-1375

SOURCE Gracell

http://www.gracellbio.com

Global Hemophilia Gene Therapy Market 2020 Impact of COVID-19, Future Growth Analysis and Challenges | Spark Therapeutics, Ultragenyx, Shire PLC,…

Posted on July 24, 2020 by Danzig

The Global Hemophilia Gene Therapy Market report focuses on market size, status and forecast 2020-2027, along with this, report also focuses on market opportunities and treats, risk analysis, strategic and tactical decision-making and evaluating the market. The Hemophilia Gene Therapy market report provides data and information on changing investment structure, technological advancements, market trends and developments, capacities, and detail information about the key players of the global Maarket_Keyword market. In addition to this, report also involves development of the Hemophilia Gene Therapy market in major region across the world.

Key Players for Global Hemophilia Gene Therapy Market:

The global Hemophilia Gene Therapy market report profiles major key players of the market on the basis of business strategies, financial weaknesses and strengths and recent development.

Spark TherapeuticsUltragenyxShire PLCSangamo TherapeuticsBioverativBioMarinuniQureFreeline Therapeutics

Get Free Sample PDF (including full TOC, Tables and Figures) of Hemophilia Gene Therapy Market @ https://www.apexmarketreports.com/Life-Science/global-hemophilia-gene-therapy-market-by-product-type360149#sample

The Hemophilia Gene Therapy market report also states demand and supply figures, revenue, production, import/export consumption as well as future strategies, sales volume, gross margins, technological developments, cost and growth rate. The Global Hemophilia Gene Therapy Market report also delivers historical data from 2015 to 2020 and forecasted data from 2020 to 2027, along with SWOT analysis data of the market. This report includes information by types, by application, by region and by manufacturers or producers.

The recent outburst of the COVID-19 (Corona Virus Disease) has led the global Hemophilia Gene Therapy market to render new solutions for combatting with the rising demand for protection against the virus. Due to this outbreak, remote patient monitoring, inpatient monitoring and interactive medicine is expected to gain grip at this time.

Global Hemophilia Gene Therapy Market: Segmentation

Global Hemophilia Gene Therapy Market Segmentation: By Types

Hemophilia AHemophilia B

Global Hemophilia Gene Therapy Market segmentation: By Applications

Hemophilia A Gene TherapyHemophilia B Gene Therapy

Global Hemophilia Gene Therapy Market Segmentation: By Region

Global Hemophilia Gene Therapy market report categorized the information and data according to the major geographical regions like,

Place Inquiry for Buying or Customization of Report: https://www.apexmarketreports.com/Life-Science/global-hemophilia-gene-therapy-market-by-product-type360149#inquiry

The Global Hemophilia Gene Therapy market is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and OpportunitiesChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13: Hemophilia Gene Therapy Research Findings and Conclusion, Appendix, methodology and data source

A Two-part Caregiver Empowerment and Wellness – upnorthvoice.com

Posted on July 24, 2020 by Danzig

Caregiver Empowerment and WellnessVirtualConferences

Region 9Area Agency on Aging is presenting atwo-partCaregiver Empowerment and WellnessVirtualConferencevia ZoomonFriday,July 31, 2020 from 10:00 am to12:00 pmand Friday, August 14, 2020from1:00pm to2:30pm.With thestatus of the pandemic,Region 9s priority is to continue to provide support to local family caregiversthat are unable to leave the home due to the Coronavirusby providing virtual options.All caregivers are welcome to attend this free, informative, and interactive virtual conference.

This years keynote speaker will be renowned dementia care trainer andauthor of Personal Positioning for the Caregiver,JillGafnerLivingston, BSBM, CDP, CADDCT. Jill will be presenting on two important topics: Caregiver Survival and Understanding Dementia. Other topics includeCaregiver Wellness,Adaptive Equipment,and Community Resources. There will be greatdoorprizesgiven out at the end of each virtual conference.

Formore information or to register pleasecontactmainvilleb@nemcsa.org,989.358.4616,or go towww.nemcsa.org/services/senior-services/caregiver.html.This event is hosted byRegion 9 Area Agency on Aging withgold level sponsorship byMoms Meals Nourish Care.

Region 9 Area Agency on Agingis adivision of division of Northeast Michigan Community Service Agency (NEMCSA), a Community Action Agency improving the quality of life for people facing crisis while strengthening families, communities, seniors and children since 1968. To find out more information regarding NEMCSAs programs and services, please visit http://www.nemcsa.org

###

UpNorthVoice.com and Up North Voice are Northern Michigans source for community news.

We cover seven counties that include the following communities: Waters, Hale, Roscommon, St. Helen, Houghton Lake, Prudenville, Grayling, Frederic, Gaylord, Johannesburg, Lewiston, Atlanta, Comins, Fairview, Mio, Rose City, West Branch, Lupton, Skidway Lake, Sand Lake area, Glennie, Oscoda, East Tawas, Tawas City, and National City.

We are also a full-service commercial design and printing house. Our specialty is custom commercial printing, as well as the creation of clothing, cups and other marketing products.

To submit information for publication, or for questions regarding promotion of your business, please email mconstance@UpNorthVoice.com, or call 989-275-1170.

#Waters #Hale #Roscommon #St. Helen #Houghton Lake #Prudenville #Grayling #Frederic #Gaylord #Johannesburg #Lewiston #Atlanta #Comins #Fairview #Mio #Rose City #West Branch #Lupton #Skidway Lake #SandLakearea #Glennie #Oscoda #EastTawas #TawasCity #National City. @upnorthvoice1

Up North Voice is a division of AuSable Media Group, LLC, based at 709 Lake Street in Roscommon.

View post:

A Two-part Caregiver Empowerment and Wellness - upnorthvoice.com

Dance lets this Corona resident express anything and everything – Press-Enterprise

Posted on July 24, 2020 by Danzig

Joanne Olivo fell in love with dancing when she took her first class at 4 years old. By the time she got to middle school, however, it was musical theater that began to capture her attention.

But I always found myself a bit more interested in learning the choreography, the now 25-year-old Corona resident said.

Olivo continued in musical theater through her time at La Sierra High School and into enrolling at Riverside City College. While taking the required acting and music classes, she was also required to take dance technique. Olivo remembers being involved in a Performance Riverside production and RCCs dance concert at the same time. She then realized what captivated her more.

Dance gave me the freedom to express anything and everything while creating my own script and even interpreting movement as I wanted to, rather than being given guidelines in which I had to perform, she said.

After that first Riverside City College dance concert, Olivo began to take more dance technique classes and soon became part of the dance program.

The artistic freedom that I am given as a dancer is rewarding and learning from so many choreographers, teachers and dancers is a constant reminder of why I chose dance as a career path, she said.

Olivo has trained in ballet, jazz, modern and musical theater for six years. Those technique classes taught by Riverside City College dance faculty have been instrumental in her development as a dancer, she said. She went on to perform with Intersect Dance Theater Company, led by the late Sofia Carreras, whose choreographic process and style she counts as a tremendous influence.

I have recently started training at Infuse Dance Studio and am part of their company, Animus, which consists of all incredibly strong and diverse women directed by April MacLean, Olivo said.

One of Olivos favorite performances was a piece titled Pick-a-little-New-talk-a-little choreographed by Robyn ODell for the 2019 American College Dance Association.

This piece was selected for the gala that was held at the end of the conference and holds a very special place in my heart because of the subject matter being connected to the #metoo movement, she said. Robyn integrated the casts personal experiences as women, while also highlighting our strengths.

Olivo described another piece called Pataphysique, which was choreographed by Megan Fowler-Hurst that was performed in the Riverside City College faculty concert in 2016.

The dynamics of the piece and the theatrics involved in the movement is what made me finally see myself as a dancer, she said. I saw the connection between acting and dance and how they go hand in hand.

Olivo graduated with associates degrees in musical theater, social and behavioral studies, and fine and performing arts. She has since been accepted to Cornish College of the Arts in Seattle, as well as the UC Riverside. She is continuing to look into other dance programs while training in Riverside.

Im trying to decide on the dance program that feels right for me and the type of artist I am, she said.

Her future plans include getting her masters degree and teaching dance. She believes in the power of dance to integrate real experiences and emotions, as well as its ability to serve as a form of therapy.

This art form also gives many different artists a voice and provides ways to raise awareness about specific topics such as womens empowerment, LGBTQ rights and the Black Lives Matter movement, she said.

Olivio went on to discuss how an audience member might be struggling with something that isnt largely represented, but when they see a specific phrase of movement it could express exactly what theyve been feeling without saying a word.

Thats why I feel representation of diversity is extremely important to show in the dance community so that it speaks to all kinds of people who come from all walks of life, she said.

Patrick Brien is executive director of theRiverside Arts Council.

See original here:

Dance lets this Corona resident express anything and everything - Press-Enterprise

$600 unemployment benefit: What to do when it stops – Tennessean

Posted on July 24, 2020 by Danzig

With the $600 weekly federal unemployment supplement ending this week, thousands of unemployed Tennesseans are likely to be scrambling to make ends meet.

The $600 weeklysupplement, used by so many whose employment was impacted by the pandemic to tide them over, ends with the week ending July 25.

Many are predicting increased bankruptcies and strains on social service agenciesas people struggle to afford basics like rent, food, medical care and utilities.

"We know families will be hurt the most, with parentsout of work and school going remote (hampering low-income families from receiving free or reduced-cost lunches for their children)," said Samantha Williams, director of the Nashville Financial Empowerment Center, which provides free one-on-one financial counseling to any Davidson County resident.

"We hope people are finding out about usand seeing that we can help them negotiate this," she said. "I think a lot of people have been holding off asking for help while they have been getting the checks, but now we hope they will seek usout."

We asked Williams and her staff tooffer some tips to help people who face looming financial challenges.

Don't be afraid to ask for help. Call 2-1-1 for information on food, shelter and basic needs. The counselors can also help connect people with other local resourcessuch as SNAP food nutrition or TANF (Temporary Assistance for Needy Families)if they have children. The center doesnot provide financial assistance but offers to help people negotiate the system to get help.

Work with a professional financial counselor.To make a virtual appointment with aNashville Financial Empowerment Center counselor,call 615-748-3620 or visit fec.nashville.gov. The service is free for Davidson County residents, and the wait time for an appointment is about a week.

More: The $600-per-week unemployment benefit has not been extended: Here's what to know

Prioritize expenses. Make a list of allthe things you spend money on. The counselors suggest that you break itinto three categories: essentials, debt payments and discretionary spending. Essentials include housing, utilities, transportation, medical needs, basic food/grocery, child care and cellphone.

Cut where you can.Eliminate as much discretionary spending as possibleand then start trying to trim the rest.

List your debts.The counselors suggest making a call list of everyone you owe money to, thencontact each company, explain your situation and ask what your options are.

Avoid overdraft charges. Cancel automatic debits to temporarily avoid overdraft.

Don't resort to credit cards orloans.The counselors say to "exhaust every possible option" before resorting to using credit cards, personal loans or cashing out retirement to pay for current expenses.

Track your progress.Look at income and expenses to determine realistic cash flow and figure out how much wiggle room you might have on groceries and other expenses.

Learn new skills while unemployed.TheAmerican Job Center and https://www.jobs4tn.gov/vosnet/Default.aspxare good resources for finding programs where you can learn new skills while unemployed.

The Financial Empowerment Center offersfree one-on-one financial advice services toany Davidson County resident, regardless of income.

The counseling sessions are done by phone or virtually. Most initial sessions last an hour or hour and a half. To make an appointment, call 615-748-3620 or go to fec.nashville.gov.

Since March 2013, the Financial Empowerment Center has helped more than 8,000 clientsand held more than 23,000 individual counseling sessions.

The program, which has counselors who speak Spanish as well as English, hashelped its clients reduce their debt by more than $15.3million. Counselors have backgrounds in various areas, including banking and social work.

The program started in Nashville in 2013, with initial funding from the Cities for Financial Empowerment Fund, a Bloomberg Philanthropy. Now it is funded by the Mayor's Office and United Way.

Details: fec.nashville.gov andhttps://www.unitedwaynashville.org/programs/financial-empowerment-center

The extra $600 in weekly unemployment benefits was passed as part of the federal CARES Act in March. It is notexpectedto be extended past theweek ending July 25.

Reach Ms. Cheap at 615-259-8282 or mscheap@tennessean.com. Follow her on Facebook at facebook.com/mscheap, and at Tennessean.com/mscheap, and on Twitter @Ms_Cheap, and catch her every Thursday at 11 a.m. on WTVF-Channel 5s Talk of the Town.

Read or Share this story: https://www.tennessean.com/story/news/2020/07/23/600-unemployment-benefit-what-do-when-stops/5488661002/

Kindness Is a Strong Foundation for Success – Grit Daily

Posted on July 24, 2020 by Danzig

Years ago, when problems arose in my business, I realized my emotions tended to drive the decisions. When emotions are high, logic is low leading to irrational decisions. I was told it was wise to take feelings out of the decision-making process. People wanted me to focus only on the bottom line The numbers are all that matter, they said.

Numbers dont lie, we all know that. But it felt wrong in my gut to be so cold and impersonal when considering my brand. Your intuitive voice doesnt lie either. I founded my first business at my kitchen table to produce a product I needed. To me, it was personal. Analyzing the numbers is important, but dont get so caught up in them that you lose sight of your customers and your employees. If you dont care, why should they?

Entrepreneurs need to create a symbiotic relationship between the numbers and their intuition. Its a powerful heart and mind combination to help guide your business decisions. The a final, crucial piece to this equation is kindness.

Strong, amazing female business leaders often tell me they have lost the sense of who they are. They no longer treat others with the kindness and respect they want and expect themselves. We have to be true to our authentic selves. Ignoring our feelings and our intuition when making decisions is absolutely incorrect. Our kindness as a great parent, friend, and partner has a place in our business life as well. You know what is right, what you are capable of, and how you need kindness in both your personal and business lives. Do this, and everyone benefits.

Incorporating kindness into your brand messaging and business dealings is key. People want to believe that a brand is authentic and true. Consider the choices you are making during the COVID pandemic. Many people are opting to support local small businesses where they know the entrepreneurs, like their brand values, or know what theyve done to benefit the community. These are the ties that bind customers to your brand in todays challenging and ever-changing world.

Empower your staff, value them, communicate with them often, and offer incentives and recognition for ideas that are outside the box. This will improve employee satisfaction, retention and productivity.

Consumers love positive experiences, so give them one. Drive loyalty by giving dependable, personalized, top-notch customer service, with exceptional products that maintain a high-level of standards. Listen to your consumers concerns and regardless of their demeanor, respond with kindness.

In 2015, I started #ThinkKindness to help foster kindness as a principal foundation for a successful business, relationship or fulfillment of individual potential. To kick-start it, I invited 150 women to a ThinkKindness event. Making this a women-only gathering was deliberate because, unfortunately, women are often the hardest on other women. We need to respect, support and be kind to other women.

After the sale of my first company, I wondered what would be my next act in life. Then the calls started coming in from early to mid-stage entrepreneurs and CEOs reaching out for mentorship and guidance. Female entrepreneurs and CEOs, in particular, lack a strong community to help them work through the challenges that arise building and running a brand. Therefore in early 2019, I founded Pink Talented Angels By Lizanne Falsetto. Its a safety net of female founders supporting one another, in both the good times and the bad, through my Holistic Success Method, which intertwines business opportunities and personal goals for a better whole life.

By being kind and helping out others just for the sake of it, youre not only marketing your business in a positive way, but youll find a sense of empowerment in helping others that is incredibly rewarding.

My first business started and succeeded on the trifecta of paying attention to my intuition, the numbers, and kindness. Intuition pushed me to start the business, and was also my best advisor. The numbers provided a better understanding of my product line, manufacturing costs, market space, consumers and end goal. Kindness opened doors and put my product on the shelves of Trader Joes, Whole Foods and Walmart. Kindness helped me build my startup into a successful lifestyle brand. The answers you need for your business has to come from the relationship between all three.

Visit link:

Kindness Is a Strong Foundation for Success - Grit Daily

University of Chester nursing students shortlisted for national award – The Chester Standard

Posted on July 24, 2020 by Danzig

A GROUP of nursing students from the University of Chester has been shortlisted for a prestigious national award for its work in representing the student voice.

The Student Empowerment Group has been named as a finalist in this years RCNi Nurse Awards in the category of Nursing Student of the Year.

The purpose of the group was to ensure that the Nursing and Midwifery Councils (2018) theme of student empowerment in nurse education was integrated into the new curriculum.

The university performed particularly strongly in listening to its student body in this years National Student Survey (NSS).

The group was set up in August 2018 by students Daniel Branch, Rose James, Hannah Dixon, Thomas Slater and Charina Guanzon with senior lecturer Peg Murphy.

They meet monthly and attend programme planning meetings with lecturers and staff in the universitys Faculty of Health and Social Care with the aim of giving students a real voice in developing their programmes of study.

As the workload increased, the group worked with the lecturer to develop a business plan to create student empowerment consultants who would be paid for their work.

Daniel and Rose are now the co-chairs of the group and with new members in place they have worked on a new curriculum; given presentations about their work; developed guidance for students going on their placements and are working on compiling a collection of reflections on student experiences on placement to help others feel more comfortable and share learning.

Daniel chairs the meetings and up to 30 staff and students attend. He has also co-designed and delivered a poster about the groups work and presented it at the HEE (Higher Education England) Learner Wellbeing Conference 2020: Championing Mental Wellbeing in the NHS.

Rose was part of the programme planning team panel and has represented the student voice at all of the meetings and discussed these opinions with staff and students at all levels. She has been recognised for her work going above and beyond within the University and was awarded the Tom Mason prize for working.

Thomas and Hannah are now newly qualified nurses.

Daniel said: "We are very proud that being part of the student empowerment group has enabled us to help our fellow students to become the best nurses they can be, both now and in the future, and are pleased to have been able to improve our personal skills particularly in relation to communication and advocacy.

"We feel that the more empowered nurses feel the better the care they are able to provide and have been able to see the personal benefits of this during our practice placements."

Professor Angela Simpson, executive dean of the Faculty of Health and Social Care, said: I am immensely proud of the hard work and dedication of the Student Empowerment Group. To be shortlisted for such an award is testament to their commitment to giving students at the University a real voice.

The awards celebrate innovation, skill and dedication in nursing and showcase excellence in the profession. The winners will be announced in a virtual ceremony later this year.

University of Chester nursing students shortlisted for national award - The Chester Standard

Select Page ::